The study tested a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear cell renal cell carcinoma — a type of kidney cancer. After undergoing tumor-removing surgery, the patients received their personalized vaccine at Boston’s Dana-Farber Cancer Institute.
Standard treatment for these patients is surgery to remove the tumor followed by pembrolizumab (Keytruda), but two-thirds of patients face cancer recurrence, according to a news release from Dana-Farber Cancer Institute.
About three years after the vaccine administration, all patients remained cancer-free. No dose-limiting toxicities were observed, either, from the initial doses and two booster shots.
Larger clinical trials are needed to confirm the vaccine’s efficacy, the researchers said.
Nature published the phase 1 results Feb. 5.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
